Company
(location)

Partner
(location)

Amt.

(M)

Details

Date

TOTAL: $185.35M (YEAR TO DATE: $185.35M)

Elusys Therapeutics Inc. (Pine Brook, N.J.)

U.S. government

$16.35

For completing the second delivery of Anthim (obiltoxaximab) for inhalational anthrax

1/25/17

Eyegate Pharmaceuticals Inc. (Waltham, Mass.)

Valeant Pharmaceuticals International Inc.

ND

As part of the license agreement for worldwide commercial and manufacturing rights to the Eyegate II Delivery System and EGP-437 combination product for uveitis

1/10/17

Genmab A/S (Copenhagen)

Janssen (unit of Johnson & Johnson; New Brunswick, N.J.)

$25

For achieving the first sales volume milestone in its 2012 Darzalex (daratumumab) collaboration, for sales of the drug reaching $500M in a calendar year

1/9/17

Innate Pharma SA (Marseille, France)

Bristol-Myers Squibb Co. (New York)

$15

For continued exploration of lirilumab in combination with Opdivo (nivolumab), following encouraging results from the cohort of patients with squamous cell cancer of the head and neck of a phase I/II trial, indicating that targeting both pathways may provide enhanced clinical activity, particularly in PD-L1 positive tumors, with deep and durable responses in some patients

1/10/17

Mannkind Corp. (Valencia, Calif.)

Receptor Life Sciences Inc. (Seattle)

$1

As part of a January 2016 deal focused on developing multiple inhaled therapeutic products for conditions such as chronic pain, neurologic diseases and inflammatory disorders

1/4/17

Ossianix Inc. (Philadelphia)

H. Lundbeck A/S (Copenhagen)

ND

For completion of the objectives in a 2014 research agreement focusing on both technology development and the delivery of antibody therapeutics to the brain via the blood-brain barrier; Ossianix uses the single domain shark VNAR scaffold to engineer products, including monospecific and bispecific antibodies

1/27/17

Phenex Pharmaceutical AG (Germany)

Gilead Sciences Inc. (Foster City, Calif.)

$100

For GS-9674, a farnesoid X receptor agonist, entering phase II development

1/6/17

Spark Therapeutics Inc. (Philadelphia)

Pfizer Inc. (New York)

$15

For achieving a pre-specified safety and efficacy profile development milestone in the ongoing phase I/II trial of its gene therapy candidate, SPK-9001, in hemophilia B

1/5/17

Xenetic Biosciences Inc. (Lexington, Mass.)

Shire plc (Dublin)

$3

For the advancement of the PSA-recombinant SHP656, or factor VIII (fVIII), into a phase I/IIa study in hemophilia

1/9/17

Zealand Pharma A/S (Copenhagen)

Sanofi SA (Paris)

$10

For the European Commission granting marketing authorization for Suliqua, the once-daily titratable fixed-dose ratio combination of basal insulin glargine 100 units/mL and GLP-1 receptor agonist lixisenatide, to treat type 2 diabetes

1/18/17

Zymeworks Inc. (Vancouver, British Columbia)

Eli Lilly and Co. (Indianapolis)

ND

For hitting a milestone in a second immune-modulating bispecific antibody in its collaborations using Zymeworks' Azymetric platform

1/6/17

Notes

Currency conversions are based on exchange rates at the time of the deal.

The date indicated refers to the BioWorld Today issue in which the news item can be found.

This chart includes only biotech companies that develop therapeutics.

ND = Not disclosed.